| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2579 |
| Trial ID | NCT04728347 |
| Disease | COVID-19 |
| Altered gene | VEEV|S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | ARCT-021 |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 |
| Year | 2021 |
| Country | Singapore |
| Company sponsor | Arcturus Therapeutics, Inc. |
| Other ID(s) | ARCT-021-02 |
| Vector information | |||
|
|||
| Cohort1: ARCT-021 | |||||||
|
|||||||
| Cohort2: No Intervention | |||||||
|
|||||||